Skip to main content
Regeneron8-K: Major contract win

Regeneron Secures BARDA Agreement to Supply Inmazeb for Ebola Preparedness Through 2031

Source: Autobound Signal API · 94 signals tracked for Regeneron · updated

Get Regeneron's live signals in Claude or ChatGPT, or by API

AskWhat changed at Regeneron this week? Use Autobound signals for regeneron.com.

What happened

Regeneron announced an agreement with BARDA to provide additional supply of Inmazeb for U.S. Ebola preparedness, delivering doses annually from 2027 through 2031. This long-term federal contract may drive investments in specialized biomanufacturing and compliance tooling.

Source

SEC EDGAROct 30, 2026

Current report (Form 8-K)

Regeneron 8-K

Filing excerpt

In October 2026, the Company announced an agreement with the Biomedical Advanced Research and Development Authority (BARDA) to provide additional supply of Inmazeb® for U.S. preparedness against Ebola disease. Under the terms of the agreement, the Company expects to deliver a pre-specified number of treatment doses of Inmazeb each year to the U.S. government beginning in 2027 through 2031.

sec.gov/Archives/edgar/data/872589/000087258926000032/regn-20261030.htmRead the full source

Other signals in this filing (2)

Extracted by Autobound

From the Signal API record
Signal
8-K: Major contract win

What this signalsFilings often name leadership changes, deals and spending plans.

Form
8-K
Fiscal year end
10/30
Filed
Oct 30, 2026

The full record

From the Signal API record

Details

CIK
872589
Accession number
0000872589-26-000032
Timeframe
Multi year
Filing year
2026
Why it matters
Scaling needs
Signal category
Revenue

Topics and mentions

Regions named

  • U.S.

Extraction

Confidence
High
Relevance
80%
Sentiment
Positive
Detected
Nov 3, 2026
signal_type
sec-8k
signal_subtype
majorContractWin

Use this data

Get every 8-K signal for Regeneron and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Regeneron this week?”

  2. Send it to your own tools

    The Signal API returns 8-K signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full sec-8k record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/7bd4ea46-7775-4cca-a101-3e4547d24333 returns this record as JSON. POST /v1/companies/enrich returns every signal for regeneron.com.

{
  "signal_id": "7bd4ea46-7775-4cca-a101-3e4547d24333",
  "signal_type": "sec-8k",
  "signal_subtype": "majorContractWin",
  "detected_at": "2026-11-03T07:04:59.413+00:00",
  "company": {
    "name": "Regeneron",
    "domain": "regeneron.com"
  },
  "data": {
    "detail": "Regeneron announced an agreement with BARDA to provide additional supply of Inmazeb for U.S. Ebola preparedness, delivering doses annually from 2027 through 2031. This long-term federal contract may drive investments in specialized biomanufacturing and compliance tooling.",
    "metrics": {
      "timeframe": "multi_year"
    },
    "summary": "Regeneron Secures BARDA Agreement to Supply Inmazeb for Ebola Preparedness Through 2031",
    "excerpts": "In October 2026, the Company announced an agreement with the Biomedical Advanced Research and Development Authority (BARDA) to provide additional supply of Inmazeb® for U.S. preparedness against Ebola disease. Under the terms of the agreement, the Company expects to deliver a pre-specified number of treatment doses of Inmazeb each year to the U.S. government beginning in 2027 through 2031.",
    "relevance": 0.8,
    "sentiment": "positive",
    "confidence": "high",
    "source_url": "https://www.sec.gov/Archives/edgar/data/872589/000087258926000032/regn-20261030.htm",
    "filing_date": "2026-10-30",
    "filing_year": 2026,
    "fiscal_year_end": "10/30",
    "sales_relevance": "Scaling needs",
    "signal_category": "revenue",
    "regions_mentioned": [
      "U.S."
    ]
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.